IMANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
ImageneBio, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026
$4.00−0.04 (-0.99%)
Close on Oct 19, 2026
- Market cap
- $64.65M
- P/E (TTM)
- –
- Dividend yield
- –
Ownership
Institutional holdings as of Jun 30, 2026, from 13F filings
Held by institutions
54.9%
6M of 11M shares
Institutional holders
35
4 new, 8 sold out
Net institutional buying
1M
In Q2 2026
Insider trades, 12 months
1 buys · 2 sales
Net bought $78.51K
Shares held by institutions
Holders of more than 5%
Latest Schedule 13D (active) or 13G (passive) filed by each holder
| Holder | Shares | % of class | Filing | As of |
|---|---|---|---|---|
| Blue Owl Capital Holdings LP | 959,337 | 8.51% | 13G (passive) amendment | Mar 31, 2026 |
| Otello Stampacchia | 936,222 | 8.40% | 13D (active) | Apr 14, 2026 |
| Deep Track Capital, LP | 878,516 | 7.86% | 13G (passive) | Jul 28, 2025 |
| Bvf Partners L P/Il | 802,102 | 7.20% | 13G (passive) amendment | Sep 30, 2025 |
| Ma-Weaver Jacob | 643,933 | 5.80% | 13G (passive) | Dec 29, 2025 |
| Bvf Inc/Il | 4,006,564 | 8.30% | 13G (passive) amendment | Dec 31, 2024 |
| Orbimed Advisors LLC | 1,495,045 | 13.10% | 13D (active) amendment | Apr 14, 2026 |
| Trails Edge Capital Partners, LP | 1,176,472 | 9.90% | 13G (passive) | Apr 14, 2026 |
| Lampert Mark N | 1,128,647 | 9.90% | 13G (passive) amendment | Jun 30, 2026 |
Top institutional holders
13F holdings as of Jun 30, 2026
| Holder | Shares | % of IMA | Value | Change | % of portfolio |
|---|---|---|---|---|---|
| Bvf Inc/Il | 1,110,002 | 9.78% | $6.55M | – | 0.17% |
| Blue Owl Capital Holdings LP | 917,692 | 8.08% | $5.41M | −41,645 | 0.81% |
| Orbimed Advisors LLC | 909,269 | 8.01% | $5.36M | +530,713 | 0.10% |
| Cable Car Capital, LP | 781,599 | 6.89% | $4.61M | +26,850 | 0.10% |
| Omega Fund Management, LLC | 455,361 | 4.01% | $2.69M | – | 1.45% |
| Rtw Investments, LP | 334,445 | 2.95% | $1.97M | – | 0.02% |
| Vanguard Capital Management LLC | 320,518 | 2.82% | $1.89M | −4,637 | 0.00% |
| Trails Edge Capital Partners, LP | 282,004 | 2.48% | $1.66M | New | 0.26% |
| BML Capital Management, LLC | 200,730 | 1.77% | $1.18M | – | 0.67% |
| Monashee Investment Management LLC | 192,344 | 1.69% | $1.13M | New | 1.90% |
| BlackRock, Inc. | 135,090 | 1.19% | $797.03K | +5,876 | 0.00% |
| Renaissance Technologies LLC | 86,930 | 0.77% | $512.89K | +5,234 | 0.00% |
| Adage Capital Partners Gp, L.L.C. | 66,666 | 0.59% | $393.33K | – | 0.00% |
| Citadel Advisors LLC | 55,610 | 0.49% | $328.10K | −68,735 | 0.00% |
| Geode Capital Management, LLC | 53,512 | 0.47% | $315.76K | −6,417 | 0.00% |
| NEA Management Company, LLC | 50,005 | 0.44% | $295.03K | – | 0.02% |
| Nano Cap New Millennium Growth Fund L P | 50,000 | 0.44% | $295.00K | +20,000 | 0.23% |
| Hsbc Holdings PLC | 34,228 | 0.30% | $208.45K | −656 | 0.00% |
| Sofinnova Investments, Inc. | 31,884 | 0.28% | $188.12K | – | 0.01% |
| Vanguard Fiduciary Trust Co | 27,475 | 0.24% | $162.10K | +189 | 0.00% |
Institutional buying and selling by quarter
Positions opened, added to, reduced and closed by 13F filers
| Quarter | Holders | Shares held | % of shares | New / added | Reduced / closed | Shares bought | Shares sold |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 35 | 6M | 54.9% | 4 / 9 | 12 / 8 | 1M | 0M |
| Q1 2026 | 39 | 5M | 47.2% | 7 / 16 | 7 / 8 | 1M | 0M |
| Q4 2025 | 41 | 5M | 42.3% | 14 / 12 | 6 / 6 | 1M | 1M |
| Q3 2025 | 33 | 5M | 41.8% | 33 / 0 | 0 / 0 | 5M | 0M |
Top mutual fund and ETF holders
Latest monthly portfolio reports (Form N-PORT)
| Fund | Shares | % of IMA | Value | % of fund | As of |
|---|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 264,771 | 2.33% | $1.56M | 0.00% | Jun 30, 2026 |
| Vanguard Extended Market Index Fund | 52,467 | 0.46% | $309.56K | 0.00% | Jun 30, 2026 |
| Fidelity Extended Market Index Fund | 31,679 | 0.28% | $180.57K | 0.00% | May 31, 2026 |
| iShares Micro-Cap ETF | 26,707 | 0.24% | $157.57K | 0.01% | Jun 30, 2026 |
| Fidelity Series Total Market Index Fund | 7,299 | 0.06% | $41.60K | 0.00% | May 31, 2026 |
| Fidelity Total Market Index Fund | 5,821 | 0.05% | $33.18K | 0.00% | May 31, 2026 |
| Fidelity Nasdaq Composite Index Fund | 4,219 | 0.04% | $24.05K | 0.00% | May 31, 2026 |
| Vanguard Balanced Index Fund | 3,280 | 0.03% | $19.35K | 0.00% | Jun 30, 2026 |
| 1290 VT Micro Cap Portfolio | 1,787 | 0.02% | $10.54K | 0.00% | Jun 30, 2026 |
| Total Stock Market Index Trust | 434 | 0.00% | $2.56K | 0.00% | Jun 30, 2026 |
Officers, directors and major owners
People who filed Forms 3, 4 or 5 in the last two years
| Name | Role | Shares owned | % of shares | Latest filing |
|---|---|---|---|---|
| Kristin Yarema | Chief Executive Officer, Director | 493,705 | 4.35% | Aug 17, 2026 |
| Yanina Grant-Huerta | Chief Financial Officer | 65,000 | 0.57% | Aug 17, 2026 |
| Robert B. Lally | Principal Accounting Officer | 55,582 | 0.49% | Jul 20, 2026 |
| Benjamin Porter-Brown | Chief Medical Officer | – | – | Feb 20, 2026 |
| Erin Butler | Principal Accounting Officer | 25,551 | 0.23% | Jan 2, 2026 |
| Yufang Lu | Chief Medical Officer | – | – | Aug 7, 2025 |
| Jotin Marango | Chief Financial Officer | 15,776 | 0.14% | Jul 29, 2025 |
| Joseph P. Slattery | Director | 16,000 | 0.14% | Jun 18, 2026 |
| Otello Stampacchia | Director | 455,361 | 4.01% | Jun 18, 2026 |
| David P. Bonita | Director | 753,441 | 6.64% | Jun 18, 2026 |
| Jonathan Jian Wang | Director | 1,115,005 | 9.82% | Jun 18, 2026 |
| Wei-guo Su | Director | – | – | Apr 16, 2026 |
| Advisors Llc Orbimed | Director | 287,885 | 2.54% | Apr 16, 2026 |
| Capital GP VI LLC OrbiMed | Director | 2,251,218 | 19.83% | Apr 16, 2026 |
| Genesis GP LLC OrbiMed | Director | 753,062 | 6.63% | Apr 16, 2026 |
| Stephen Hui Wang | Director | 250,721 | 2.21% | Dec 22, 2025 |
Insider trades
Common stock transactions reported on Form 4, newest first
| Insider | Date | Transaction | Shares | Price | Value | Shares after |
|---|---|---|---|---|---|---|
| Yanina Grant-Huerta Chief Financial Officer | Aug 14, 2026 | Award | +65,000 | – | – | 65,000 |
| Yanina Grant-Huerta Chief Financial Officer | Aug 14, 2026 | Award | +39,000 | – | – | 104,000 |
| Kristin Yarema Chief Executive Officer, Director | Aug 14, 2026 | Award | +254,800 | – | – | 493,705 |
| Kristin Yarema Chief Executive Officer, Director | Jul 25, 2026 | Option exercise | +38,376 | – | – | 123,776 |
| Kristin Yarema Chief Executive Officer, Director | Jul 25, 2026 | Other | +115,129 | – | – | 238,905 |
| Robert B. Lally Principal Accounting Officer | Jul 17, 2026 | Sale | −1,525 | $5.34 | $8.14K | 55,582 |
| Robert B. Lally Principal Accounting Officer | Jul 16, 2026 | Sale | −1,671 | $5.50 | $9.19K | 57,107 |
| Kristin Yarema Chief Executive Officer, Director | Mar 16, 2026 | Award | +85,400 | – | – | 85,400 |
| Erin Butler Principal Accounting Officer | Dec 30, 2025 | Award | +22,500 | – | – | 25,551 |
| Joseph P. Slattery Director | Dec 24, 2025 | Buy | +16,000 | $5.99 | $95.84K | 16,000 |
| Jotin Marango Chief Financial Officer | Jul 28, 2025 | Award | +15,776 | – | – | 15,776 |
| Jotin Marango Chief Financial Officer | Jul 28, 2025 | Tax withholding | −4,630 | $17.16 | $79.45K | 11,146 |
| Stephen Hui Wang Director | Jul 25, 2025 | Award | +50,144 | – | – | 50,144 |
| Stephen Hui Wang Director | Jul 25, 2025 | Award | +12,535 | – | – | 12,535 |
| Stephen Hui Wang Director | Jul 25, 2025 | Award | +188,042 | – | – | 188,042 |
| Jonathan Jian Wang Director | Jul 25, 2025 | Award | +971,173 | – | – | 971,173 |
| Jonathan Jian Wang Director | Jul 25, 2025 | Award | +143,832 | – | – | 143,832 |
| David P. Bonita Director | Jul 25, 2025 | Buy | +83,611 | $29.90 | $2.50M | 287,885 |
| David P. Bonita Director | Jul 25, 2025 | Option exercise | +379 | – | – | 379 |
| Otello Stampacchia Director | Jul 25, 2025 | Option exercise | +379 | – | – | 379 |
| Otello Stampacchia Director | Jul 25, 2025 | Buy | +267,556 | $29.90 | $8.00M | 454,982 |
| Advisors Llc Orbimed Director | Jul 25, 2025 | Award | +83,611 | $2.49 | $208.19K | 287,885 |
| Erin Butler Principal Accounting Officer | Jul 25, 2025 | Award | +3,051 | – | – | 3,051 |
| David P. Bonita Director | Aug 4, 2023 | Award | +153,121 | – | – | 5,582,144 |
| Advisors Llc Orbimed Director | Aug 4, 2023 | Award | +153,121 | – | – | 5,582,144 |
| David P. Bonita Director | Aug 4, 2023 | Award | +153,121 | – | – | 2,251,218 |
| Capital GP VI LLC OrbiMed Director | Aug 4, 2023 | Award | +153,121 | – | – | 2,251,218 |
| David P. Bonita Director | Jun 24, 2022 | Buy | −96,035 | $5.37 | $515.71K | 2,098,097 |
| David P. Bonita Director | Jun 24, 2022 | Buy | −65,965 | $4.37 | $288.27K | 2,002,062 |
| Capital GP VI LLC OrbiMed Director | Jun 24, 2022 | Buy | −96,035 | $5.37 | $515.71K | 2,098,097 |
| Capital GP VI LLC OrbiMed Director | Jun 24, 2022 | Buy | −65,965 | $4.37 | $288.27K | 2,002,062 |
| David P. Bonita Director | Jun 23, 2022 | Buy | −23,419 | $3.71 | $86.88K | 1,936,097 |
| Capital GP VI LLC OrbiMed Director | Jun 23, 2022 | Buy | −23,419 | $3.71 | $86.88K | 1,936,097 |
| David P. Bonita Director | Jun 22, 2022 | Buy | −66,806 | $3.55 | $237.16K | 1,912,678 |
| Capital GP VI LLC OrbiMed Director | Jun 22, 2022 | Buy | −66,806 | $3.55 | $237.16K | 1,912,678 |
| Maude Tessier Chief Business Officer | Jan 18, 2022 | Option exercise | +38,915 | $2.94 | $114.41K | 67,707 |
| Maude Tessier Chief Business Officer | Jan 18, 2022 | Option exercise | +24,606 | $4.15 | $102.11K | 92,313 |
| Maude Tessier Chief Business Officer | Jan 18, 2022 | Option exercise | +8,265 | $4.51 | $37.28K | 100,578 |
| Xiaoyan Michelle Zhang Chief Scientific Officer | Jan 11, 2022 | Option exercise | +964 | $2.15 | $2.07K | 45,439 |
| Xiaoyan Michelle Zhang Chief Scientific Officer | Jan 11, 2022 | Sale(10b5-1 plan) | −964 | $12.00 | $11.57K | 44,475 |
| Xiaoyan Michelle Zhang Chief Scientific Officer | Jan 10, 2022 | Sale(10b5-1 plan) | −36 | $12.00 | $432 | 44,475 |
| Xiaoyan Michelle Zhang Chief Scientific Officer | Jan 10, 2022 | Option exercise | +36 | $2.15 | $77 | 44,511 |
| Atlas Venture Associates Opportunity I, LLC 10% owner | Dec 14, 2021 | Sale | −5,959 | $14.00 | $83.43K | 1,241,935 |
| Jean Francois Formela Director | Dec 14, 2021 | Sale | −5,959 | $14.00 | $83.43K | 1,241,935 |
| Atlas Venture Associates Opportunity I, LLC 10% owner | Dec 13, 2021 | Sale | −8,330 | $14.64 | $121.95K | 1,247,894 |
| Jean Francois Formela Director | Dec 13, 2021 | Sale | −8,330 | $14.64 | $121.95K | 1,247,894 |
| Atlas Venture Associates Opportunity I, LLC 10% owner | Dec 10, 2021 | Sale | −11,989 | $15.03 | $180.19K | 1,256,224 |
| Jean Francois Formela Director | Dec 10, 2021 | Sale | −11,989 | $15.03 | $180.19K | 1,256,224 |
| Xiaoyan Michelle Zhang Chief Scientific Officer | Dec 10, 2021 | Option exercise | +1,000 | $2.15 | $2.15K | 45,475 |
| Xiaoyan Michelle Zhang Chief Scientific Officer | Dec 10, 2021 | Sale | −1,000 | $14.76 | $14.76K | 44,475 |
| Atlas Venture Associates Opportunity I, LLC 10% owner | Mar 30, 2021 | Buy | +125,000 | $16.00 | $2.00M | 874,634 |
| Jean Francois Formela Director | Mar 30, 2021 | Buy | +125,000 | $16.00 | $2.00M | 874,634 |
| David P. Bonita Director | Mar 30, 2021 | Buy | +375,000 | $16.00 | $6.00M | 1,845,872 |
| David P. Bonita Director | Mar 30, 2021 | Conversion | +5,429,023 | – | – | 5,429,023 |
| David P. Bonita Director | Mar 30, 2021 | Buy | +48,400 | $16.00 | $774.40K | 91,014 |
| David P. Bonita Director | Mar 30, 2021 | Conversion | +157,288 | – | – | 157,288 |
| David P. Bonita Director | Mar 30, 2021 | Conversion | +42,614 | – | – | 42,614 |
| David P. Bonita Director | Mar 30, 2021 | Conversion | +1,470,872 | – | – | 1,470,872 |
| Genesis GP LLC OrbiMed Director | Mar 30, 2021 | Conversion | +1,470,872 | – | – | 1,470,872 |
| Genesis GP LLC OrbiMed Director | Mar 30, 2021 | Conversion | +42,614 | – | – | 42,614 |
Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.